Brig­gs Mor­ri­son helms new MPM on­col­o­gy start­up with Pfiz­er Ven­tures, Po­laris part­ners on board

Brig­gs Mor­ri­son has a new on­col­o­gy biotech in the works.

Syn­dax Phar­ma­ceu­ti­cals said on March 30 that Mor­ri­son was de­part­ing as head of R&D. And now we know why: The long­time in­dus­try ex­ec­u­tive, at one point the chief med­ical of­fi­cer at As­traZeneca, is now CEO and di­rec­tor for MPM Cap­i­tal’s Cross­bow Ther­a­peu­tics, ac­cord­ing to an SEC fil­ing this week.

The Cam­bridge, MA biotech is hunt­ing down an $80 mil­lion round, per the fi­nan­cial doc­u­ment, which out­lines a board com­prised of MPM man­ag­ing di­rec­tor Todd Fo­ley, Pfiz­er Ven­tures part­ner Ire­na Mel­niko­va and Po­laris Part­ners’ Alexan­dra Cant­ley. For­mer MPM se­nior as­so­ciate Geral­dine Paulus is a co-founder and VP of cor­po­rate de­vel­op­ment and op­er­a­tions, per a LinkedIn pro­file.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER